These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 32474411)

  • 21. TIGIT and PD-1 Immune Checkpoint Pathways Are Associated With Patient Outcome and Anti-Tumor Immunity in Glioblastoma.
    Raphael I; Kumar R; McCarl LH; Shoger K; Wang L; Sandlesh P; Sneiderman CT; Allen J; Zhai S; Campagna ML; Foster A; Bruno TC; Agnihotri S; Hu B; Castro BA; Lieberman FS; Broniscer A; Diaz AA; Amankulor NM; Rajasundaram D; Pollack IF; Kohanbash G
    Front Immunol; 2021; 12():637146. PubMed ID: 34025646
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunomodulation for glioblastoma.
    Reardon DA; Wen PY; Wucherpfennig KW; Sampson JH
    Curr Opin Neurol; 2017 Jun; 30(3):361-369. PubMed ID: 28368867
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An Update on the Role of Immunotherapy and Vaccine Strategies for Primary Brain Tumors.
    Neagu MR; Reardon DA
    Curr Treat Options Oncol; 2015 Nov; 16(11):54. PubMed ID: 26454859
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Developing immunotherapeutic strategies to target brain tumors.
    Lieberman NA; Moyes KW; Crane CA
    Expert Rev Anticancer Ther; 2016 Jul; 16(7):775-88. PubMed ID: 27253692
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HOXC6/8/10/13 predict poor prognosis and associate with immune infiltrations in glioblastoma.
    Yu M; Yu S; Zhou W; Yi B; Liu Y
    Int Immunopharmacol; 2021 Dec; 101(Pt A):108293. PubMed ID: 34763232
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Extrinsic factors associated with the response to immunotherapy in glioblastoma.
    Bi H; Zhang C
    Cancer Lett; 2021 Jul; 511():47-55. PubMed ID: 33933551
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune Checkpoint Blockade Biology in Mouse Models of Glioblastoma.
    Yeo AT; Charest A
    J Cell Biochem; 2017 Sep; 118(9):2516-2527. PubMed ID: 28230277
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized controlled phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy of newly diagnosed glioblastoma (GlioVax): study protocol for a randomized controlled trial.
    Rapp M; Grauer OM; Kamp M; Sevens N; Zotz N; Sabel M; Sorg RV
    Trials; 2018 May; 19(1):293. PubMed ID: 29801515
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Current challenges in designing GBM trials for immunotherapy.
    Weathers SP; Gilbert MR
    J Neurooncol; 2015 Jul; 123(3):331-7. PubMed ID: 25577401
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Advanced Imaging Techniques for Differentiating Pseudoprogression and Tumor Recurrence After Immunotherapy for Glioblastoma.
    Li Y; Ma Y; Wu Z; Xie R; Zeng F; Cai H; Lui S; Song B; Chen L; Wu M
    Front Immunol; 2021; 12():790674. PubMed ID: 34899760
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel Immunotherapeutics for Treatment of Glioblastoma: The Last Decade of Research.
    Khansur E; Shah AH; Lacy K; Komotar RJ
    Cancer Invest; 2019; 37(1):1-7. PubMed ID: 30632816
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immune microenvironments differ in immune characteristics and outcome of glioblastoma multiforme.
    Zhang B; Shen R; Cheng S; Feng L
    Cancer Med; 2019 Jun; 8(6):2897-2907. PubMed ID: 31038851
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prospects of immune checkpoint modulators in the treatment of glioblastoma.
    Preusser M; Lim M; Hafler DA; Reardon DA; Sampson JH
    Nat Rev Neurol; 2015 Sep; 11(9):504-14. PubMed ID: 26260659
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunotherapy for Neuro-oncology.
    Majd NK; Dasgupta PR; de Groot JF
    Adv Exp Med Biol; 2021; 1342():233-258. PubMed ID: 34972967
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nanotechnology to augment immunotherapy for the treatment of glioblastoma multiforme.
    Ung N; Yang I
    J Neurooncol; 2015 Jul; 123(3):473-81. PubMed ID: 26070553
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interleukin-13 receptor alpha 2-targeted glioblastoma immunotherapy.
    Sengupta S; Thaci B; Crawford AC; Sampath P
    Biomed Res Int; 2014; 2014():952128. PubMed ID: 25247196
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunotherapy targeting glioma stem cells--insights and perspectives.
    Li Z; Lee JW; Mukherjee D; Ji J; Jeswani SP; Black KL; Yu JS
    Expert Opin Biol Ther; 2012 Feb; 12(2):165-78. PubMed ID: 22200324
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Global immune fingerprinting in glioblastoma patient peripheral blood reveals immune-suppression signatures associated with prognosis.
    Alban TJ; Alvarado AG; Sorensen MD; Bayik D; Volovetz J; Serbinowski E; Mulkearns-Hubert EE; Sinyuk M; Hale JS; Onzi GR; McGraw M; Huang P; Grabowski MM; Wathen CA; Ahluwalia MS; Radivoyevitch T; Kornblum HI; Kristensen BW; Vogelbaum MA; Lathia JD
    JCI Insight; 2018 Nov; 3(21):. PubMed ID: 30385717
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intratumor injection of CCL21-coupled vault nanoparticles is associated with reduction in tumor volume in an in vivo model of glioma.
    Voth BL; Pelargos PE; Barnette NE; Bhatt NS; Chen CHJ; Lagman C; Chung LK; Nguyen T; Sheppard JP; Romiyo P; Mareninov S; Kickhoefer VA; Yong WH; Rome LH; Yang I
    J Neurooncol; 2020 May; 147(3):599-605. PubMed ID: 32274629
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [What's next in glioblastoma treatment: Tumor-targeted or immune-targeted therapies?].
    Schernberg A; Marabelle A; Massard C; Armand JP; Dumont S; Deutsch E; Dhermain F
    Bull Cancer; 2016 May; 103(5):484-98. PubMed ID: 27032303
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.